Targeting of circulating Th17 cells by β-D-mannuronic acid (M2000) as a novel medication in patients with rheumatoid arthritis
ConclusionM2000 shows the inhibitory effect on the frequency of circulating Th17 cells as well as in the production of IL-17 in RA patients.
Source: Inflammopharmacology - Category: Drugs & Pharmacology Source Type: research
More News: Arthritis | Clinical Trials | Drugs & Pharmacology | Enbrel | Rheumatoid Arthritis | Rheumatology | Study